AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9180659 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint education (RE)
Number of subjects: 643
Study 9180659 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 643
Study 8204290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg b.d. for 8 days (25 patients)
Number of subjects: 47
Study 8204290 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate 500 mg t.d.s for 8 days (22 patients)
Number of subjects: 47
Study 3110441 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lumen catheter (SLC)
Number of subjects: 75
Study 3110441 — intervention group
Group type: COMPARATOR
Intervention: Triple lumen catheter (TLC)
Number of subjects: 75
Study 31999174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 853
Study 31999174 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 853
Study 29064872 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 5%
Number of subjects: 100
Study 29064872 — intervention group
Group type: COMPARATOR
Intervention: Balanced hydroxyethyl starch 6% (130/0.4)
Number of subjects: 100
Study 28914359 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 19
Study 28914359 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia
Number of subjects: 19
Study 25532076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/day
Number of subjects: 312
Study 25532076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 22913568 — intervention group
Group type: EXPERIMENTAL
Intervention: LACA using the Arctic Front® catheter
Number of subjects: 37
Study 22913568 — intervention group
Group type: EXPERIMENTAL
Intervention: LACA using the HD Mesh Ablator® catheter
Number of subjects: 37
Study 22913568 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Arctic Front® and HD Mesh Ablator®)
Number of subjects: 37
Study 21427078 — intervention group
Group type: EXPERIMENTAL
Intervention: C24T variant allele in MRP2 under macrolides treatment (Tacrolimus and Sirolimus)
Number of subjects: 66
Study 21427078 — intervention group
Group type: EXPERIMENTAL
Intervention: C24T variant allele in MRP2 under cyclosporine treatment
Number of subjects: 66
Study 21427078 — intervention group
Group type: EXPERIMENTAL
Intervention: C3972T variant allele in MRP2
Number of subjects: 66
Study 18308218 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen plus ibuprofen (AcIBU)
Number of subjects: 146
Study 18308218 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine plus caffeine (Tylenol No. 3)
Number of subjects: 146
Study 16681972 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stapler combined with prolapsing technique
Number of subjects: 43
Study 16681972 — intervention group
Group type: COMPARATOR
Intervention: Conventional double stapler technique
Number of subjects: 43
Study 14498816 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive musical mood induction
Number of subjects: 109
Study 14498816 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative musical mood induction
Number of subjects: 109
Study 14498816 — intervention group
Group type: COMPARATOR
Intervention: No-music control condition
Number of subjects: 109
Study 10875715 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg x kg(‐1) (R/M15 group)
Number of subjects: 210
Study 10875715 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.20 mg x kg(‐1) (R/M20 group)
Number of subjects: 210
Study 10875715 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (F group)
Number of subjects: 210
Study 9106381 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted bath
Number of subjects: 10
Study 9106381 — intervention group
Group type: COMPARATOR
Intervention: Control day (no bath)
Number of subjects: 10
Study 29498350 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate vitamin D3 supplementation
Number of subjects: 0
Study 29498350 — intervention group
Group type: COMPARATOR
Intervention: Higher vitamin D intake
Number of subjects: 0
Study 27142170 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus S-1 (IRI-S)
Number of subjects: 126
Study 27142170 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 126
Study 25431126 — intervention group
Group type: EXPERIMENTAL
Intervention: Starfix® frames
Number of subjects: 60
Study 25431126 — intervention group
Group type: COMPARATOR
Intervention: Conventional stereotactic frames
Number of subjects: 60
Study 23062389 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol 320 μg/day
Number of subjects: 107
Study 23062389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 23062389 — intervention group
Group type: COMPARATOR
Intervention: Placebo/prednisone (prednisone 10 mg/day for the last 7 days)
Number of subjects: 107
Study 19551827 — intervention group
Group type: EXPERIMENTAL
Intervention: BKV nephropathy patients
Number of subjects: 49
Study 19551827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 19551827 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific amino acid change (aspartic acid-to-asparagine at residue 75)
Number of subjects: 49
Study 16823241 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV administration of NIC
Number of subjects: 30
Study 16823241 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV and oral administration of NIC
Number of subjects: 30
Study 16823241 — intervention group
Group type: COMPARATOR
Intervention: No treatment with NIC (Control group)
Number of subjects: 30
Study 15678619 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe 50 mg
Number of subjects: 442
Study 15678619 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe 250 mg
Number of subjects: 442
Study 15678619 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe 750 mg
Number of subjects: 442
Study 15678619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 11269391 — intervention group
Group type: EXPERIMENTAL
Intervention: Early educational intervention (full‐time, high‐quality, educational child care from infancy to age 5)
Number of subjects: 104
Study 11269391 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool cognitive gains
Number of subjects: 104
Study 8978584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg plus dexamethasone 20 mg (8 mg group)
Number of subjects: 80
Study 8978584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 24 mg plus dexamethasone 20 mg (24 mg group)
Number of subjects: 80
Study 8496472 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate overdentures
Number of subjects: 74
Study 8496472 — intervention group
Group type: COMPARATOR
Intervention: Immediate complete dentures
Number of subjects: 74
Study 3317935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride
Number of subjects: 60
Study 3317935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29188425 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban for 35‐42 days
Number of subjects: 7513
Study 29188425 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban
Number of subjects: 7513
Study 29188425 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin for 10 ± 4 days
Number of subjects: 7513
Study 26555033 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 17
Study 26555033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 17
Study 26555033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26162481 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 210
Study 23199009 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐1.0 μg calcitriol and 1,200 IU (30 μg) cholecalciferol
Number of subjects: 61
Study 23199009 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 IU cholecalciferol
Number of subjects: 61
Study 23199009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20572581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with daily low-dose carboplatin (arm II)
Number of subjects: 164
Study 20572581 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (arm I)
Number of subjects: 164
Study 20572581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with daily low-dose carboplatin (arm II) in stage IV disease
Number of subjects: 164
Study 20572581 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (arm I) in stage IV disease
Number of subjects: 164
Study 19133521 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 67
Study 19133521 — intervention group
Group type: EXPERIMENTAL
Intervention: Local perianal nerve block (LA) with bupivacaine
Number of subjects: 67
Study 19133521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SA and LA
Number of subjects: 67
Study 16532872 — intervention group
Group type: EXPERIMENTAL
Intervention: Shin Saver orthosis treatment group
Number of subjects: 25
Study 16532872 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional treatment)
Number of subjects: 25
Study 14556865 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal coronary culprit artery lesion location
Number of subjects: 2488
Study 14556865 — intervention group
Group type: EXPERIMENTAL
Intervention: Planimetered distance from the ostium to the LAD culprit lesion
Number of subjects: 2488
Study 10696885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischiorectal fossa block (Group 1)
Number of subjects: 20
Study 10696885 — intervention group
Group type: COMPARATOR
Intervention: No ischiorectal fossa block (Group 2)
Number of subjects: 20
Study 9381549 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microg/kg rhIL-10
Number of subjects: 21
Study 9381549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg rhIL-10
Number of subjects: 21
Study 9381549 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg rhIL-10
Number of subjects: 21
Study 9381549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8472567 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood conservation device incorporated into the arterial pressure monitoring system
Number of subjects: 100
Study 8472567 — intervention group
Group type: COMPARATOR
Intervention: Control group with conventional arterial pressure monitoring system
Number of subjects: 100
Study 3536293 — intervention group
Group type: EXPERIMENTAL
Intervention: Trientine 300 mg daily
Number of subjects: 23
Study 3536293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29447772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily
Number of subjects: 1572
Study 29447772 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 75-160 mg daily
Number of subjects: 1572
Study 28241775 — intervention group
Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life: Mind, Body and Spirit intervention, delivered through eight lessons during a summer basketball camp and one lesson with parent/trusted adult.
Number of subjects: 0
Study 28241775 — intervention group
Group type: COMPARATOR
Intervention: Control condition, details not specified.
Number of subjects: 0
Study 25941174 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ozone levels on the day before a PCV
Number of subjects: 1447
Study 25941174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day mean ozone levels before a PCV
Number of subjects: 1447
Study 25941174 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PM2.5 levels on the day before a PCV (December to March)
Number of subjects: 1447
Study 25941174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hours of sunshine (September to November)
Number of subjects: 1447
Study 25941174 — intervention group
Group type: EXPERIMENTAL
Intervention: Atmospheric pressure (April to June)
Number of subjects: 1447
Study 25941174 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature (April to August)
Number of subjects: 1447
Study 23258435 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterglass Intervention Program
Number of subjects: 46
Study 23258435 — intervention group
Group type: COMPARATOR
Intervention: Private tutoring (Control)
Number of subjects: 46
Study 22007711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Education Unit (DEU) model with clinical teacher mentoring
Number of subjects: 12
Study 18438215 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐second WAnT protocol
Number of subjects: 96
Study 16615715 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Imagery (VI)
Number of subjects: 0
Study 16615715 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-Vision (FV)
Number of subjects: 0
Study 16615715 — intervention group
Group type: COMPARATOR
Intervention: No-Vision (NV)
Number of subjects: 0
Study 15504288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence administration of lamivudine and interferon alpha 1b
Number of subjects: 150
Study 15504288 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 150
Study 15504288 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 1b
Number of subjects: 150
Study 15504288 — intervention group
Group type: COMPARATOR
Intervention: No anti-virus therapy (control group)
Number of subjects: 150
Study 11083676 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual setting (U) of NPSV, IPS 16 +/- 3 cm H(2)O, PEEPe 3.6 +/- 1.4 cm H(2)O
Number of subjects: 23
Study 11083676 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic setting (PHY) of NPSV, IPS 15 +/- 3 cm H(2)O, PEEPe 3.1 +/- 1.6 cm H(2)O
Number of subjects: 23
Study 9307197 — intervention group
Group type: EXPERIMENTAL
Intervention: Preradiation chemotherapy consisting of methotrexate 120 mg/m2, cisplatin 100 mg/m2, 5-fluorouracil 1000 mg/m2 for five days, leucovorin 25 mg/m2 every six hours for 6 doses, followed by radiation therapy and adjuvant IFN-beta (10^5 U/kg) 3 times a week for 6 months.
Number of subjects: 22
Study 9307197 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with a cumulative dose of 59.4 Gy to primary sites and 45 Gy to the neck area.
Number of subjects: 22
Study 8354807 — intervention group
Group type: EXPERIMENTAL
Intervention: Central administration of adenosine (3 mg)
Number of subjects: 30
Study 8354807 — intervention group
Group type: EXPERIMENTAL
Intervention: Central administration of adenosine (6 mg)
Number of subjects: 30
Study 8354807 — intervention group
Group type: EXPERIMENTAL
Intervention: Central administration of adenosine (9 mg)
Number of subjects: 30
Study 8354807 — intervention group
Group type: COMPARATOR
Intervention: Peripheral administration of adenosine (3 mg)
Number of subjects: 30
Study 8354807 — intervention group
Group type: COMPARATOR
Intervention: Peripheral administration of adenosine (6 mg)
Number of subjects: 30
Study 8354807 — intervention group
Group type: COMPARATOR
Intervention: Peripheral administration of adenosine (9 mg)
Number of subjects: 30
Study 8354807 — intervention group
Group type: COMPARATOR
Intervention: Peripheral administration of adenosine (12 mg)
Number of subjects: 30
Study 3575578 — intervention group
Group type: EXPERIMENTAL
Intervention: Family management approach
Number of subjects: 36
Study 3575578 — intervention group
Group type: COMPARATOR
Intervention: Individual management approach
Number of subjects: 36
Study 31714397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer Feedback (PF)
Number of subjects: 99
Study 31714397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer Feedback + Motivational Messaging (PF + MM)
Number of subjects: 99
Study 31714397 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 99
Study 31714397 — intervention group
Group type: COMPARATOR
Intervention: Motivational Messaging (MM)
Number of subjects: 99
Study 31230831 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 0
Study 31230831 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 0
Study 27989691 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic training program once per week for six weeks
Number of subjects: 51
Study 27989691 — intervention group
Group type: COMPARATOR
Intervention: Land-based training program once per week for six weeks
Number of subjects: 51
Study 27989691 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic training program
Number of subjects: 51
Study 27989691 — intervention group
Group type: COMPARATOR
Intervention: Land-based training program
Number of subjects: 51
Study 25577748 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stress SPECT MPI
Number of subjects: 272
Study 25577748 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical cardiac risk classification
Number of subjects: 272
Study 24101860 — intervention group
Group type: EXPERIMENTAL
Intervention: Betesil® plaster applied for 12 hours immediately after the procedure
Number of subjects: 20
Study 24101860 — intervention group
Group type: COMPARATOR
Intervention: Aescin 10% cream applied immediately after the procedure, in the evening, and the morning after
Number of subjects: 20
Study 21843889 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 active pills + 7 placebo pills (21/7 COC)
Number of subjects: 60
Study 21843889 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 active pills + 4 placebo pills (24/4 COC)
Number of subjects: 60
Study 20923537 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 13
Study 20923537 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 13
Study 20923537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin
Number of subjects: 13
Study 17885297 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal CRP concentration (> 10 mg/l)
Number of subjects: 606
Study 17885297 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CRP concentration
Number of subjects: 606
Study 15153210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 6 mg.kg(‐1) per oral
Number of subjects: 80
Study 15153210 — intervention group
Group type: COMPARATOR
Intervention: Sour cherry juice alone
Number of subjects: 80
Study 11445752 — intervention group
Group type: EXPERIMENTAL
Intervention: POST
Number of subjects: 15
Study 11445752 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 15
Study 11445752 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE
Number of subjects: 15
Study 9564606 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10, 30, or 60 mg/day for three or more weeks)
Number of subjects: 0
Study 9564606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pargyline (90 mg/day for three or more weeks)
Number of subjects: 0
Study 9564606 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline (30 mg/day for three or more weeks)
Number of subjects: 0
Study 9564606 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (higher doses than 10 mg/day)
Number of subjects: 0
Study 9564606 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline and Pargyline (highest doses)
Number of subjects: 0
Study 7816786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA)
Number of subjects: 900
Study 7816786 — intervention group
Group type: COMPARATOR
Intervention: Control NSAIDs
Number of subjects: 900
Study 3055740 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 109
Study 3055740 — intervention group
Group type: COMPARATOR
Intervention: Day hospital treatment
Number of subjects: 109
Study 3055740 — intervention group
Group type: COMPARATOR
Intervention: Home treatment
Number of subjects: 109
Study 30522389 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported disability measures
Number of subjects: 0
Study 30522389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility performance measures
Number of subjects: 0
Study 30522389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measures
Number of subjects: 0
Study 31362061 — intervention group
Group type: EXPERIMENTAL
Intervention: OLE treatment
Number of subjects: 419
Study 31362061 — intervention group
Group type: COMPARATOR
Intervention: Standard respiratory care (Control)
Number of subjects: 419
Study 28708931 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (CIA)
Number of subjects: 182
Study 28708931 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (FIA)
Number of subjects: 182
Study 28708931 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin and cytarabine (historical control)
Number of subjects: 182
Study 26299740 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab + mFOLFOX6
Number of subjects: 1
Study 26299740 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab + mFOLFOX6
Number of subjects: 1
Study 23980349 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaozhi Capsule (XZC)
Number of subjects: 120
Study 23980349 — intervention group
Group type: COMPARATOR
Intervention: Xuezhikang Capsule (XZKC)
Number of subjects: 120
Study 20827664 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 128
Study 20827664 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 2 h glucose levels in oGTT
Number of subjects: 128
Study 20827664 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight change
Number of subjects: 128
Study 17853008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/daily for 4 weeks
Number of subjects: 90
Study 17853008 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg on demand for 4 weeks plus levofloxacin 250 mg daily for the first week
Number of subjects: 90
Study 16597040 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil (25 mg once a day for 4 weeks)
Number of subjects: 106
Study 12809971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/d
Number of subjects: 1000
Study 11001109 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (7VPnC) administered as a separate injection
Number of subjects: 368
Study 11001109 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (7VPnC) combined with Haemophilus influenzae type b vaccine (HbOC)
Number of subjects: 368
Study 11001109 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccines only (control group)
Number of subjects: 368